Modus Therapeutics AB is a clinical-stage drug development company that develops pharmaceutical therapies to restore impaired blood flow and oxygen transport in rare diseases with unmet medical need.
The company’s development portfolio includes sevuparin, a drug used to treat people suffering from sickle cell disease.
Its sevuparin drug holds the ability to restore blood flow during microvascular obstructions by exerting its anti-adhesive effects to treat inherited blood disorders and various malarial diseases. The company was founded in 2011 and is based in Stockholm, Sweden. Modus Therapeutics AB operates as a subsidiary of Dilafor AB.